Relationship amongp53, stage, and prognosis of large bowel cancer

Autor: Nathanson, S. David, Linden, Michael D., Tender, Paul, Zarbo, Richard J., Jacobsen, Gordon, Nelson, Lisa T.
Zdroj: Diseases of the Colon & Rectum; June 1994, Vol. 37 Issue: 6 p527-534, 8p
Abstrakt: PURPOSE: We designed a study to determine whether increases inp53protein in primary carcinomas of the colon or rectum correlate with overall survival. Mutations of the tumor suppressor genep53are detectable by immunocytochemical methods in colorectal cancers because of accumulation of nuclearp53protein. METHODS: IgG1 monoclonal antibody to humanp53protein (PAb 1801) was used to detectp53in formalin-fixed, paraffin-embedded archival tumors resected from 84 patients with tumor limited to the bowel wall. A multivariate analysis was performed using five prognostic pathobiologic variables compared with the level of staining of thep53product. RESULTS: Nuclearp53protein was observed in 52 (62 percent) of 84 colorectal cancer patients with Stage T2 or T3, N0, M0 disease. Patients with strong expression (3+ and 4+) ofp53appeared to die from their disease sooner than those with weak expression (1+ and 2+), although this was not statistically significant (P >0.59). Thirty-two patients did not express nuclearp53by immunocytochemical methods. When these patients were analyzed in combination with the strongp53expressors, the trend toward decreased survival increased (P>0.15). CONCLUSIONS: This data suggest that lack ofp53expression may also predict an adverse outcome in colorectal cancer. However, before the immunocytochemical method can be used clinically as a prognostic indicator, the colorectal cancer patients with zero expression should be studied further to clarify the functional status ofp53in their tumors.
Databáze: Supplemental Index
Externí odkaz: